StockNews.AI
VNDA
StockNews.AI
134 days

Vanda Pharmaceuticals Announces Presentation at 2025 AAN Annual Meeting

1. Vanda announces participation at 2025 AAN Annual Meeting in San Diego. 2. Presentation of a new therapy, VCA-894A, for CMT2S on April 9, 2025. 3. VCA-894A shows significant improvements in neuromuscular function and has FDA orphan designation. 4. Research emphasizes advancements in precision medicine and patient-specific treatments. 5. Poster includes novel unpublished data, potentially increasing interest from stakeholders.

5m saved
Insight
Article

FAQ

Why Bullish?

The presentation of VCA-894A highlights innovation, which may attract investors and increase stock value. Similar cases in biotech show significant stock rebounds after promising data presentations.

How important is it?

The focus on a novel therapeutic aligned with unmet medical needs indicates strong potential for future developments and market success, enhancing VNDA's overall profile.

Why Long Term?

As VCA-894A progresses, successful outcomes could lead to increased patient demand and market penetration over time, similar to other gene therapies achieving rapid growth post-approval.

Related Companies

VRTXNBIXAMGNREGN
, /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at the American Academy of Neurology (AAN) Annual Meeting, to be held in San Diego, California from April 5 through April 9, 2025.  The following will be presented: April 9, 2025  Presentation Title: "Translating IGHMBP2 Variants with a CMT2S Patient-specific Organ-on-a-chip Model: Personalized Medicine ASO-based Therapeutic Rescue" Poster Presentation Session: P-12 Poster Number: 11-017 Presenter: Dr. Sandra Paulina Smieszek, Head of Genetics This poster describes the data around a novel breakthrough therapeutic (VCA-894A) customized to a specific genetic mutation of a patient with Charcot-Marie-Tooth disease type 2S (CMT2S). The effects of VCA-894A were confirmed in Hesperos' Human-on-a-Chip® neuromuscular junction model with patient-derived cells where VCA-894A demonstrated significant improvements in neuromuscular function, including reduced muscle fatigue and improved synaptic transmission between motor neurons and skeletal muscle myotubes. The use of a microphysiological system to evaluate the effects of a genetically tailored treatment represents a significant advancement in precision medicine and the use of human relevant methods of evaluation. VCA-894A has been granted an orphan designation by the FDA and it is expected to soon be administered to the specific patient for whom it was developed. The experimental platform described in this poster has the potential to unlock the development of treatments that can address significantly unmet medical needs based on genetic understandings and precision medicine. Vanda has previously published an article titled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S."  In addition to the data published in the article, this poster will present some novel unpublished data on conduction velocity.  For access to the full article, visit DOI: 10.1016/j.omtn.2025.102479. For more information on potential ASO-based personalized treatment for CMT2S, please see Vanda's prior announcement, available here.  For more information on the AAN Annual Meeting, please refer to www.aan.com.  About Vanda Pharmaceuticals Inc. Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X @vandapharma. Corporate Contact: Kevin MoranSenior Vice President, Chief Financial Officer and Treasurer  Vanda Pharmaceuticals Inc. 202-734-3400 [email protected] Jim Golden / Jack Kelleher / Dan Moore Collected Strategies [email protected] SOURCE Vanda Pharmaceuticals Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News